Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAM 1110

Drug Profile

BAM 1110

Latest Information Update: 12 Dec 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Maruko Seiyaku
  • Developer Azwell; Maruko Seiyaku
  • Class Antiparkinsonians; Neuroprotectants; Small molecules
  • Mechanism of Action Dopamine D1 receptor agonists; Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure; Hypertension; Parkinson's disease

Most Recent Events

  • 22 Sep 2000 No-Development-Reported for Heart failure in Japan (Unknown route)
  • 22 Sep 2000 No-Development-Reported for Hypertension in Japan (PO)
  • 22 Sep 2000 No-Development-Reported for Parkinson's disease in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top